Antibody Responses during Hepatitis B Viral Infection

PLoS Computational Biology

Volumn 10, Issue 7, 2014, Pages

  Ciupe, Stanca M ^a   Ribeiro, Ruy M ^b   Perelson, Alan S ^b  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACIDS; VIRUSES;

ANTIBODIES RESPONSE; CHRONIC DISEASE; DNA VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS INFECTION; LIVER CELLS; NEUTRALISATION; VIRAL CLEARANCE; VIRAL INFECTIONS;

ANTIBODIES;

HEPATITIS B ANTIBODY; NUCLEOCAPSID PROTEIN; VIRUS PROTEIN;

ADULT; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; HEPATITIS B; HUMAN; MATHEMATICAL MODEL; VIRAL CLEARANCE; VIRUS NEUTRALIZATION; VIRUS PARTICLE; BIOLOGICAL MODEL; BIOLOGY; HEPATITIS B VIRUS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; PROCEDURES; VIROLOGY; VIRUS LOAD;

COMPUTATIONAL BIOLOGY; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, IMMUNOLOGICAL; VIRAL LOAD;

EID: 84905454876     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003730     Document Type: Article

References (71)

1. Hollinger F, Liang T (2001) Fields Virology, Philadelphia: Lippincott Williams & Wilkins. 4th edition, pp. 2971-3036.
2. Rehermann B, Nascimbeni M, (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215-229.
3. Waters J, Pignatelli M, Galpin S, Ishihara K, Thomas H, (1986) Virus-neutralizing antibodies to hepatitis B virus: The nature of an immunogenic epitope to the S gene peptide. J Gen Virol 67: 2467-2473.
4. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni A, et al. (1990) Cellular immune response to hepatitis B virus encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 145: 3442-3449.
5. Guidotti L, Ishikawa T, Hobbs M, Matzke B, Schreiber R, et al. (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4: 25-36.
6. McClary H, Koch R, Chisari F, Guidotti L, (2000) Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 74: 2255-2264.
7. Wieland S, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari F, (2005) Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci USA 102: 9913-9917.
8. Wieland S, Guidotti L, Chisari F, (2000) Intrahepatic induction of Alpha/Beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 74: 4165-4173.
9. Ciupe S, Ribeiro R, Nelson P, Dusheiko G, Perelson A, (2007) The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc Natl Acad Sci USA 104: 5050-5055.
10. Guo J, Zhou H, Liu C, Aldrich C, Saputelli J, et al. (2000) Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 74: 1495-1505.
11. Chisari F, (2000) Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 156: 1117-1132.
12. Bertoletti A, Ferrari C, (2003) Kinetics of the immune response during HBV and HCV infection. Hepatology 38: 4-13.
13. Lai C, Locarnini S (2002) Hepatitis B virus. London, UK: International Medical Press.
14. Anh-Tuan N, Novk E, Holln S, (1980) Hepatitis B surface antigen circulating immune complexes (HBsAg-CICs) in patients with bleeding disorders. J Immunol Meth 35: 307-318.
15. Brown S, Steward M, Viola L, Howard C, Murraylyon I, (1983) Chronic liver disease: the detection and characterization of circulating immune complexes. Immunology 49: 673-683.
16. Glebe D, Lorenz H, Gerlich W, Butler S, Tochkov I, et al. (2009) Correlation of virus and host response markers with circulating immune complexes during acute and chronic woodchuck hepatitis virus infection. J Virol 83: 1579-1591.
17. Rath S, Devey M, (1988) IgG subclass composition of antibodies to HBsAg in circulating immune complexes from patients with hepatitis B virus infections. Clin Exp Immunol 72: 164-167.
18. Prange R, (2012) Host factors involved in hepatitis B virus maturation, assembly, and egress. Med Microbiol Immunol 201: 449-461.
19. Ganem D, Schneider R (2001) Hepadnaviridae: The viruses and their replication. Philadelphia: Lippincot Williams & Wilkins, 4th edition, 2924 pp.
20. Glebe D, Urban S, (2007) Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 13: 22-38.
21. Ganem D, (1991) Assembly of hepadnaviral virions and subviral particles. Curr Top Microbiol Immunol 168: 61-83.
22. Gilbert R, Beales L, Blond D, Simon M, Lin B, et al. (2005) Hepatitis B small surface antigen particles are octahedral. Proc Natl Acad Sci USA 102: 14783-14788.
23. Patient R, Hourioux C, Roingeard P, (2009) Morphogenesis of hepatitis B virus and its subviral envelope particles. Cell Microbiol 11: 1561-1570.
24. Garcia T, Li J, Sureau C, Ito K, Qin Y, et al. (2009) Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion. J Virol 83: 11152-11165.
25. Nowak M, Bonhoeffer S, Hill A, Boehme R, Thomas H, et al. (1996) Viral dynamics in hepatitis B infection. Proc Natl Acad Sci USA 93: 4398-4402.
26. Nowak M, May R (2000) Virus Dynamics. Oxford: Oxford University Press.
27. Perelson A, (2002) Modelling viral and immune system dynamics. Nature Rev Immunol 2: 28-36.
28. Perelson A, Neumann A, Markowitz M, Leonard J, Ho D, (1996) HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
29. Stafford M, Corey L, Cap Y, Daar E, Ho D, et al. (2000) Modeling plasma virus concentration during primary HIV infection. J Theor Biol 203: 285-301.
30. Lewin S, Ribeiro R, Walters T, Lau G, Bowden S, et al. (2001) Analysis of hepatitis B viral load decline under potent therapy:complex decay profiles observed. Hepatology 34: 1012-1020.
31. Tsiang M, Rooney J, Toole J, Gibbs C, (1999) Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29: 1863-1869.
32. Lambotte L, Saliez A, Triest S, Tagliaferri E, Barker A, et al. (1997) Control of rate and extent of the proliferative response after partial hepatectomy. Am J Physiol 273: G905-G912.
33. Michalopoulos G, DeFrances M, (1997) Liver regeneration. Science 276: 60-66.
34. Ciupe S, Ribeiro R, Nelson P, Perelson A, (2007) Modeling the mechanisms of acute hepatitis B virus infection. J Theor Biol 247: 23-35.
35. Bonhoeffer S, May R, Shaw G, Nowak M, (1997) Virus dynamics and drug therapy. Proc Nat Acad Sci USA 94: 6971-6976.
36. Ribeiro R, Dixit N, Perelson A (2006) Modelling the in vivo growth rate of HIV: implications for vaccination. Multidisciplinary approaches to theory in medicine. Amsterdam, Netherlands: Elsevier, 231-246 pp.
37. Nowak M, May R (2001) Virus dynamics: Mathematical principles of immunology and virology. Oxford University Press.
38. Murray J, Wieland S, Purcell R, Chisari F, (2005) Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci USA 102: 17780-17785.
39. Sprengers D, van der Molen R, Kusters J, De Man R, Niesters H, et al. (2006) Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans. J Hepatol 45: 182-189.
40. Yousfi N, Hattaf K, Tridane A, (2011) Modeling the adaptive immune response in HBV infection. J Math Biol 63: 933-957.
41. Kandathil A, Graw F, Quinn J, Hwang H, Torbenson M, et al. (2013) Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterol 145: 1404-1413.
42. Dibrov B, Livshits M, Volkenstein M, (1977) Mathematical model of immune processes. J Theor Biol 65: 609-631.
43. Oprea M, Perelson A, (1996) Exploring the mechanisms of primary antibody responses to T cell-dependent antigens. J Theor Biol 181: 215-236.
44. Lodish H, Berk A, Matsudaira P, Kaiser C, Krieger M, et al. (2004) Molecular Cell Biology. San Francisco, CA: WH Freeman & Co, 5th edition.
45. Sherlock S, Dooley J (2002) Diseases of the Liver and Biliary System. Oxford: Blackwell Science, 11 edition, 1-9 pp.
46. Dahari H, Cotler S, Layden T, Perelson A, (2009) Hepatitis B virus clearance rate estimates. Hepatology 49: 1779-1780.
47. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, et al. (1996) Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). Eur J Clin Chem Clin Biochem 34: 517-520.
48. Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, et al. (2007) Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol 151: 42-50.
49. Morell A, Terry W, Waldmann T, (1970) Metabolic properties of IgG subclasses in man. J Clin Invest 49: 673-680.
50. Rossi M, Azzari C, Resti M, Appendino C, Pezzati P, et al. (1988) Selectivity in IgG subclass response to hepatitis B vaccine in infants born to HBsAg-positive mothers. Clin Exp Immunol 72: 196-200.
51. Rath S, Devey M, (1988) IgG subclass composition of antibodies to HBsAg in circulating immune complexes from patients with hepatitis B virus infections. Clin Exp Immunol 72: 164-167.
52. Schwesinger F, Ros R, Strunz T, Anselmetti D, Guntherodt HJ, et al. (2000) Unbinding forces of single antibody-antigen complexes correlate with their thermal dissociation rates. Proc Natl Acad Sci USA 97: 9972-9977.
53. Gopalakrishnan P, Karush F, (1975) Antibody affinity. VIII. measurement of affinity of anti-lactose antibody by fluorescence quenching with a DNP-containing ligand. J Immunol 114: 1359-1362.
54. Roost H, Bachmann M, Haag A, Kalinke U, Pliska V, et al. (1995) Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc Natl Acad Sci USA 92: 1257-1261.
55. Igarashi T, Brown C, Azadegan A, Haigwood N, Dimitrov D, et al. (1999) Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med 5: 211-216.
56. Webster G, Hallett R, Whalley S, Meltzer M, Balogun K, et al. (2000) Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy. Lancet 356: 379-384.
57. Whalley S, Murray J, Brown D, Webster G, Emery V, et al. (2001) Kinetics of acute hepatitis B virus infection in humans. J Exp Med 193: 847-853.
58. Klasse P, Sattentau Q, (2002) Occupancy and mechanism in antibody- mediated neutralization of animal viruses. J Gen Virol 83: 2091-2108.
59. Yang X, Lee SKS, Sodroski J, (2005) Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol 79: 3500-3508.
60. Magnus C, Regoes R, (2011) Restricted occupancy models for neutralization of HIV virions and populations. J Theor Biol 283: 192-202.
61. Magnus C, (2013) Virus neutralisation: New insights from kinetic neutralisation curves. PLoS Comput Biol 9: e1002900 doi:10.1371/journal.pcbi.1002900.
62. IgG Human ELISA Kit ab100547 http://www.abcam.com/IgG-Human-ELISA-Kit-ab100547.html.
63. Bortz D, Nelson P, (2004) Sensitivity analysis of a nonlinear lumped parameter model of HIV infection dynamics. Bull Math Biol 66: 1009-1026.
64. Tabei A, Li Y, Weigert M, Dinner A, (2012) Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV. Vaccine 30: 607-613.
65. Tomaras G, Yates N, Liu P, Qin L, Fouda G, et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin IgM and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82: 12449-12463.
66. Hadler S, Margolis H, (1992) Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. Curr Clin Top Infect Dis 12: 282-308.
67. McMahon B, Bruden D, Petersen K, Bulkow L, Parkinson A, et al. (2005) Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 142: 333-341.
68. McMahon B, Dentinger C, Bruden D, Zanis C, Peters H, et al. (2009) Antibody levels and protection after hepatitis B vaccine: Results of a 22-year follow-up study and response to a booster dose. J Inf Dis 200: 1390-1396.
69. Cejka J, Mood D, Kim C, (1974) Immunoglobulin concentrations in sera of normal children: quantitation against an international reference preparation. Clin Chem 20: 656-659.
70. Parkin D, (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044.
71. Read S, (2001) Recovery efficiencies of nucleic acid extraction kits as measured by quantitative LightCycler TM PCR. Mol Path 54: 86-90.